Business
SOPHiA GENETICS Announces L'hôpital Universitaire Avicenne is Live on SOPHiA DDM™
The hospital will use the SOPHiA DDM™ Platform to enhance its testing and research of blood cancers BOSTON and ROLLE, Switzerland, July 29, 2024 /PRNewswire/
About this update from Sophia Genetics Sa
[{"type":"text","content":"The hospital will use the SOPHiA DDM™ Platform to enhance its testing and research of blood cancers\nBOSTON and ROLLE, Switzerland, July 29, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, today announced that L'hôpital Universitaire Avicenne is implementing the SOPHiA DDM™ Platform. The hospital, located in Bobigny, France, will use the platform to advance its testing and research of blood-related cancers and disorders. \n\n \n \n \n \n \n \n\n \nL'hôpital Avicenne, which serves approximately 500,000 patients annually across all areas of care, is a clinical, research, and teaching hospital, known for its expertise in oncology. L'hôpital Avicenne's clinical hematology department treats various hematological malignancies via 25 in-patient beds and outpatient care.\n\"As a research and teaching hospital, as well as a clinical center of excellence, it is our goal to offer all of our patients advanced and personalized care,\" said Grégory Lazarian, PhD, Medical Biologist L'Hôpital Avicenne. \"By implementing the SOPHiA DDM™ Platform we will be able to expand our lymphoid testing, which will advance research and treatment planning for blood disorders and cancers.\"\nBlood cancers are the fifth most common type of cancer in the world with roughly 1.3 million new cases reported annually.1 Advances in the study of blood cancers, as with many other cancers, depend on timely, cost-effective, and reliable sequencing strategies as well as high-quality and reproducible data. The SOPHiA DDM™ Platform uses next-generation sequencing (NGS) to target key variants from FFPE, blood, or bone marrow samples helping lead to better detection of variants associated with the disease. SOPHiA DDM™ is specifically designed to compute a wide array of genomic variants and continually hone machine learning algorithms to detect genomic variants associated with rare and challenging cases.\n\"At SOPHiA GENETICS we are passionate about accelerating and expanding the use of precision medicine. This is made possible by our AI-based technology that facilitates fast and accurate analysis of key data and helps draw relevant insights for researchers and clinicians to support them in making data-driven decisions,\" said Kevin Puylaert, Managing Director, EMEA, SOPHiA GENETICS. \"L'hô...